๐ฐ Ascending Dose News
Page 2 - Ascending Dose News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ascending Dose. Real-time updates on events, politics, business and more.
August 11, 2022
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
August 11, 2022
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
May 16, 2022
-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive...
May 12, 2022
Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 Paltusotineโs Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated...
May 10, 2022
Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple
May 10, 2022
/PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the first quarter...
May 10, 2022
/PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the first quarter...
April 11, 2022
Full Data Set from Phase I First-in-Human Helped Establish Doses for Phase IIA Multiple Ascending Dose StudyATLANTA--(BUSINESS WIRE)--$ACAD #ACImmune--Alzamend Neuro, Inc. (Nasdaq: ALZN) (โAlzamendโ), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodeg...
March 18, 2022
Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodiumphenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M
March 17, 2022
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the fourth quarter...